Disentangling the Babylonian speech confusion in genetic counseling: an analysis of the reliability and validity of the nomenclature for BRCA1/2 DNA-test results other than pathogenic - PubMed (original) (raw)
Review
Disentangling the Babylonian speech confusion in genetic counseling: an analysis of the reliability and validity of the nomenclature for BRCA1/2 DNA-test results other than pathogenic
Joël Vos et al. Genet Med. 2009 Oct.
Free article
Abstract
Purpose: Effective communication of DNA-test results requires a sound terminology. However, the variety of terms in literature for DNA-test results other than pathogenic, may create inconsistencies between professionals, and misunderstanding in patients. Therefore, we conducted a theoretical and empirical analysis of the terms most frequently used in articles between 2002 and 2007 for BRCA 1/2-test results other than pathogenic.
Design: We analyzed the content validity of the no-pathogenic DNA-test result-terms by comparing the literal and intended meaning of the terms and by examining their clarity and the inclusion of all relevant information. We analyzed the reliability of the terms by measuring the strength of association between terms and their meanings and the consistency among different authors over time.
Results: Two hundred twenty-seven articles with 361 no-pathogenic DNA-test result-terms were found. Only two terms seemed to have acceptable validity: variant of uncertain clinical significance and no-pathogenic-DNA-test-result. Only variant of uncertain clinical significance and true negative were found to be used reliably in the literature.
Conclusions: Current DNA nomenclature lacks validity and reliability. Transparent DNA-test result terminology should be developed covering both laboratory findings and clinical meaning.
Similar articles
- Opening the psychological black box in genetic counseling. The psychological impact of DNA testing is predicted by the counselees' perception, the medical impact by the pathogenic or uninformative BRCA1/2-result.
Vos J, Gómez-García E, Oosterwijk JC, Menko FH, Stoel RD, van Asperen CJ, Jansen AM, Stiggelbout AM, Tibben A. Vos J, et al. Psychooncology. 2012 Jan;21(1):29-42. doi: 10.1002/pon.1864. Epub 2010 Nov 11. Psychooncology. 2012. PMID: 21072753 - Key messages for communicating information about BRCA1 and BRCA2 to women with breast or ovarian cancer: Consensus across health professionals and service users.
Jacobs C, Pichert G, Harris J, Tucker K, Michie S. Jacobs C, et al. Psychooncology. 2017 Nov;26(11):1818-1824. doi: 10.1002/pon.4379. Epub 2017 Feb 10. Psychooncology. 2017. PMID: 28101941 - Patients' resistance to risk information in genetic counseling for BRCA1/2.
Gurmankin AD, Domchek S, Stopfer J, Fels C, Armstrong K. Gurmankin AD, et al. Arch Intern Med. 2005 Mar 14;165(5):523-9. doi: 10.1001/archinte.165.5.523. Arch Intern Med. 2005. PMID: 15767527 - [Cognitive, emotional and behavioral impact of an uncertain outcome after study of BRCA1/2: review of the literature].
Leblond D, Brédart A, Dolbeault S, De Pauw A, Stoppa Lyonnet D, Flahault C, Sultan S. Leblond D, et al. Bull Cancer. 2011 Feb;98(2):184-98. doi: 10.1684/bdc.2011.1309. Bull Cancer. 2011. PMID: 21382771 Review. French. - Finding all BRCA pathogenic mutation carriers: best practice models.
Hoogerbrugge N, Jongmans MC. Hoogerbrugge N, et al. Eur J Hum Genet. 2016 Sep;24 Suppl 1(Suppl 1):S19-26. doi: 10.1038/ejhg.2016.95. Eur J Hum Genet. 2016. PMID: 27514840 Free PMC article. Review.
Cited by
- Consensus: a framework for evaluation of uncertain gene variants in laboratory test reporting.
Crockett DK, Ridge PG, Wilson AR, Lyon E, Williams MS, Narus SP, Facelli JC, Mitchell JA. Crockett DK, et al. Genome Med. 2012 May 28;4(5):48. doi: 10.1186/gm347. Genome Med. 2012. PMID: 22640420 Free PMC article. - The near Babylonian speech confusion in early detection of psychosis.
Schultze-Lutter F, Schimmelmann BG, Ruhrmann S. Schultze-Lutter F, et al. Schizophr Bull. 2011 Jul;37(4):653-5. doi: 10.1093/schbul/sbr039. Epub 2011 May 9. Schizophr Bull. 2011. PMID: 21558142 Free PMC article. No abstract available. - Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies.
Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, Church DM, Crolla JA, Eichler EE, Epstein CJ, Faucett WA, Feuk L, Friedman JM, Hamosh A, Jackson L, Kaminsky EB, Kok K, Krantz ID, Kuhn RM, Lee C, Ostell JM, Rosenberg C, Scherer SW, Spinner NB, Stavropoulos DJ, Tepperberg JH, Thorland EC, Vermeesch JR, Waggoner DJ, Watson MS, Martin CL, Ledbetter DH. Miller DT, et al. Am J Hum Genet. 2010 May 14;86(5):749-64. doi: 10.1016/j.ajhg.2010.04.006. Am J Hum Genet. 2010. PMID: 20466091 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous